BioSpace News Archive

Devonian Heath Group Inc. to Participate in Renmark’s Virtual Non-Deal Roadshow Series for Montreal and East of Canada Today June 3 rd , 2021

Studies published in two journals, International Journal of Periodontics & Restorative Dentistry and Lasers in Medical Science, support use of proprietary Er,Cr:YSGG laser technology for peri-implantitis treatments

Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Onconova has been selected to present at 2021 BIO Digital, being held virtually June 10-11 and 14-18, 2021.

Proceeds will support development of antibody drugs and discovery platform targeting pro-tumorigenic factors produced by fibroblasts in the tumor microenvironment, rendering resistant cancers treatable

Shareholder Presentation Today to Further Highlight Results HT- KIT Reduces KIT expression and induces apoptosis of neoplastic human mast cells Inhibits tumor growth in humanized xenograft mast cell neoplasia models Reduces liver infiltration of neoplastic mast cells Reduces tumor growth in isograft models of mast cell neoplasia Reduces signs of mast cell leukemia in an isograft model of mutant mast cell neoplasia

Janux Therapeutics, a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the appointment of Wayne Godfrey, M.D., as Chief Medical Officer, effective June 1, 2021.

Adaptive Phage Therapeutics Initiates Phase 1/2 Trial of PhageBank ™ in Urinary Tract Infections

Stablix Therapeutics, a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS), today announced a $63 million Series A financing led by founding investor Versant Ventures together with NEA, Cormorant, Euclidean Euclidean Capital and Alexandria Real Estate Equities.

Dermavant Sciences, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration

Forge Biologics, a gene therapy-focused contract development and manufacturing organization (CDMO), announced today the appointment of John Maslowski to the newly created role of Chief Commercial Officer.